Search results for "Pulmonary fibrosi"

showing 10 items of 96 documents

The role of mucin 1 in respiratory diseases

2020

Recent evidence has demonstrated that mucin 1 (MUC1) is involved in many pathological processes that occur in the lung. MUC1 is a transmembrane protein mainly expressed by epithelial and hematopoietic cells. It has a receptor-like structure, which can sense the external environment and activate intracellular signal transduction pathways through its cytoplasmic domain. The extracellular domain of MUC1 can be released to the external environment, thus acting as a decoy barrier to mucosal pathogens, as well as serving as a serum biomarker for the diagnosis and prognosis of several respiratory diseases such as lung cancer and interstitial lung diseases. Furthermore, bioactivated MUC1-cytoplasmi…

Pulmonary and Respiratory MedicineAnti-Inflammatory Agents03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicinePulmonary fibrosismedicineAnimalsHumansRespiratory systemLung cancerMUC1lcsh:RC705-779Lungbusiness.industryMucinMucin-1lcsh:Diseases of the respiratory systemmedicine.diseaseAsthmaIntracellular signal transductionBiomarkermedicine.anatomical_structure030228 respiratory system030220 oncology & carcinogenesisCancer researchbusinessSignal Transduction
researchProduct

Interstitial lung disease induced by drugs and radiation.

2004

An ever-increasing number of drugs can reproduce variegated patterns of naturally occurring interstitial lung disease (ILD), including most forms of interstitial pneumonias, alveolar involvement and, rarely, vasculitis. Drugs in one therapeutic class may collectively produce the same pattern of involvement. A few drugs can produce more than one pattern of ILD. The diagnosis of drug-induced ILD (DI-ILD) essentially rests on the temporal association between exposure to the drug and the development of pulmonary infiltrates. The histopathological features of DI-ILD are generally consistent, rather than suggestive or specific to the drug etiology. Thus, the diagnosis of DI-ILD is mainly made by …

Pulmonary and Respiratory MedicineDrugmedicine.medical_specialtyPathologymedia_common.quotation_subjectPulmonary FibrosisAmiodaronePulmonary EdemaMedicineHumansInterstitial pneumoniaPulmonary EosinophiliaDechallengeBronchiolitis ObliteransLungmedia_commonRadiotherapybusiness.industryRespiratory diseaseInterstitial lung diseasePneumoniarespiratory systemmedicine.diseaseDermatologyrespiratory tract diseasesPulmonary AlveoliRadiographyMethotrexateCorticosteroid therapyChronic DiseaseEtiologybusinessVasculitisLung Diseases InterstitialRespiration; international review of thoracic diseases
researchProduct

Telomerase and Telomere Length in Pulmonary Fibrosis

2013

In addition to its expression in stem cells and many cancers, telomerase activity is transiently induced in murine bleomycin (BLM)-induced pulmonary fibrosis with increased levels of telomerase transcriptase (TERT) expression, which is essential for fibrosis. To extend these observations to human chronic fibrotic lung disease, we investigated the expression of telomerase activity in lung fibroblasts from patients with interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis (IPF). The results showed that telomerase activity was induced in more than 66% of IPF lung fibroblast samples, in comparison with less than 29% from control samples, some of which were obtained from lu…

Pulmonary and Respiratory MedicineMaleTelomerasePathologymedicine.medical_specialtyClinical BiochemistryBiologyBleomycinGene Expression Regulation EnzymologicHistonesTelomerase RNA componentIdiopathic pulmonary fibrosischemistry.chemical_compoundBleomycinMiceFibrosisPulmonary fibrosismedicineAnimalsHumansEmfisema pulmonarPromoter Regions GeneticMolecular BiologyLungTelomeraseCells CulturedMice KnockoutLungAntibiotics AntineoplasticAcetylationCell BiologyArticlesFibroblastsTelomererespiratory systemmedicine.diseaseIdiopathic Pulmonary FibrosisTelomereUp-Regulationrespiratory tract diseasesmedicine.anatomical_structurechemistryPulmonsChronic DiseaseCancer researchFemaleAlveolitis Extrinsic AllergicPulmons Malalties
researchProduct

Pleuroparenchymal fibroelastosis: one more walk on the wild side of drugs?

2014

In this issue of the European Respiratory Journal , Beynat-Mouterde et al. [1] report on six young adults (three of whom were female) who developed a clinical imaging pattern of predominant upper lobe fibrosis with apical pneumothoraces (fig. 1). Presentation in all six patients was similar with cough, dyspnoea, occasional chest pain and weight loss. Imaging was distinctive and showed a cephalad, irregular, pleural-based thickening that encroached on the lung bilaterally. Five patients presented with “platythorax” (fig. 2), a preferential reduction in the anterio-posterior diameter of the chest wall. In all patients, severe restrictive or restrictive-obstructive lung dysfunction progressed …

Pulmonary and Respiratory MedicineThoraxMalemedicine.medical_specialtyLungmedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentPulmonary FibrosisAntineoplastic AgentsChest painmedicine.diseaseSurgeryChest tubemedicine.anatomical_structureRespiratory failurePneumothoraxBiopsyMedicineHumansFemalemedicine.symptombusinessChest radiographLungThe European respiratory journal
researchProduct

Psychological Profile of Patients Diagnosed With Idiopathic Pulmonary Fibrosis

2022

Pulmonary and Respiratory Medicinemedicine.medical_specialtyIdiopathic pulmonary fibrosisbusiness.industryInternal medicineMEDLINEmedicinemedicine.diseasebusinessArchivos de Bronconeumología
researchProduct

Functional Analysis in Single-Lung Transplant Recipients

2004

Objective To develop and evaluate a postprocessing tool to quantify ventilated split-lung volumes on the basis of 3 He-MRI and to apply it in patients after single-lung transplantation (SLTX). High-resolution CT (HRCT) was employed as a reference modality providing split air-filled lung volumes. Lung volumes derived from pulmonary function test results served as clinical parameters and were used as the “gold standard.” Material and methods Eight patients (mean age, 54 years) with emphysema and six patients (mean age, 58 years) with idiopathic pulmonary fibrosis. All patients were evaluated following SLTX. HRCT was performed during inspiration (slice thickness, 1 mm; increment, 10 mm). For c…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyLungmedicine.diagnostic_testbusiness.industryMagnetic resonance imagingrespiratory systemCritical Care and Intensive Care Medicinemedicine.diseaserespiratory tract diseasesPulmonary function testingTransplantationIdiopathic pulmonary fibrosismedicine.anatomical_structureHounsfield scalemedicineLung volumesRadiologyCardiology and Cardiovascular MedicinebusinessTidal volumeChest
researchProduct

The impact of SARS-COV2 pandemic on the management oF IPF patients: Our narrative experience

2021

Abstract Background The SARS-CoV-2 pandemic has changed the health-care systems around the world in a remarkable way. We describe the strategies adopted to cope with the limitations imposed by the pandemic to the access to health care by patients diagnosed with idiopathic Pulmonary Fibrosis (IPF). Material and methods We conducted a retrospective observational analysis including IPF patients under antifibrotic drugs (nintedanib and pirfenidone) that accessed to the Outpatient clinic of the University of Palermo, Italy. Patients received a phone number and an email address in case of any urgency and a virtual meeting was settled up monthly. Results 40 patients (M/F: 30/10) were followed up, …

Pulmonary and Respiratory Medicinemedicine.medical_specialtyPyridonesCOVID-19 IPF Pulmonary fibrosis SARS-CoV-2DiseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioSARS-CoV-2 severe acute respiratory syndrome coronavirus 2ArticlePulmonary fibrosis03 medical and health sciencesIdiopathic pulmonary fibrosischemistry.chemical_compound0302 clinical medicineED Emergency departmentInternal medicinePulmonary fibrosisPandemicmedicineOutpatient clinicHumansPharmacology (medical)030212 general & internal medicineIPF Idiopathic Pulmonary FibrosisPandemicsRetrospective StudiesCOVID-19 Coronavirus disease 2019business.industrySARS-CoV-2Biochemistry (medical)ARDS adult respiratory distress syndromeCOVID-19Emergency departmentPirfenidonemedicine.diseaseIdiopathic Pulmonary FibrosisIPF030228 respiratory systemchemistryHRCT High-resolution chest tomographyRNA ViralNintedanibbusinessPulmonary fibrosimedicine.drug
researchProduct

Gastroesophageal Reflux Disease and Idiopathic Pulmonary Fibrosis

2019

Pulmonary and Respiratory Medicinemedicine.medical_specialtybusiness.industryRefluxMEDLINEDiseaseCritical Care and Intensive Care Medicinemedicine.diseaseGastroenterologyIdiopathic pulmonary fibrosisInternal medicinemedicineCardiology and Cardiovascular MedicinebusinessChest
researchProduct

HSP27 : une nouvelle cible pour traiter la fibrose pulmonaire idiopathique ?

2020

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease without therapeutic options. The development of new therapeutic strategies for the disease is needed. IPF is characterized by myofibroblast accumulation and collagen overproduction. Transforming growth factor-β1 (TGF-β1) is a key cytokine activating these pathological processes. Heat shock proteins (HSPs) are crucial regulators and promote TGF-β1 activity. Among them, HSP27 is overexpressed in animal models and in the lung of patients with IPF. HSP27 activates pro-fibrotic mechanisms and therefore may represents a potential target. Strategies aiming to inhibit HSP27 might pave the way towards new treatment options for pa…

Pulmonary and Respiratory Medicinemedicine.medical_treatment[SDV]Life Sciences [q-bio]Disease03 medical and health sciencesIdiopathic pulmonary fibrosis0302 clinical medicineHsp27Heat shock proteinmedicine030212 general & internal medicineLungbiologybusiness.industryrespiratory systemmedicine.diseaserespiratory tract diseases3. Good health[SDV] Life Sciences [q-bio]medicine.anatomical_structureCytokine030228 respiratory systembiology.proteinCancer researchFatal diseasebusinessMyofibroblast
researchProduct

Extracellular Heat Shock Proteins as Therapeutic Targets and Biomarkers in Fibrosing Interstitial Lung Diseases.

2021

Interstitial lung diseases (ILDs) include a large number of diseases and causes with variable outcomes often associated with progressive fibrosis. Although each of the individual fibrosing ILDs are rare, collectively, they affect a considerable number of patients, representing a significant burden of disease. Idiopathic pulmonary fibrosis (IPF) is the typical chronic fibrosing ILD associated with progressive decline in lung. Other fibrosing ILDs are often associated with connective tissues diseases, including rheumatoid arthritis-ILD (RA-ILD) and systemic sclerosis-associated ILD (SSc-ILD), or environmental/drug exposure. Given the vast number of progressive fibrosing ILDs and the dispariti…

QH301-705.5DiseaseReviewbehavioral disciplines and activitiesCatalysisextracellular HSPInorganic ChemistryIdiopathic pulmonary fibrosisFibrosisHeat shock proteinmedicineExtracellularAnimalsHumansinterstitial lung diseasesMolecular Targeted TherapyPhysical and Theoretical ChemistryBiology (General)Molecular BiologyQD1-999SpectroscopyHeat-Shock ProteinsLungbusiness.industryOrganic Chemistrylung fibrosisCancerGeneral Medicinerespiratory systemmedicine.diseaseIdiopathic Pulmonary FibrosisComputer Science Applicationsrespiratory tract diseasesbody regionsChemistrymedicine.anatomical_structureIPFImmunologyheat shock proteinsDisease ProgressionBiomarker (medicine)biomarkerbusinessLung Diseases InterstitialBiomarkersInternational journal of molecular sciences
researchProduct